Discounted Cash Flow
Biolinerx Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | — | $-16.5m | — | — | — |
| 2017 | — | $-25.2m (-52.8%) | $-20.5m | — | — |
| 2018 | — | $-25.6m (-1.4%) | $-24.2m (-17.7%) | — | — |
| 2019 | — | $-28.1m (-9.8%) | $-22.7m (6.3%) | — | — |
| 2020 | — | $-22.9m (18.4%) | — | — | — |
| 2021 | $0 | $-24.8m (-8.1%) | $-23.6m | — | — |
| 2022 | $0 | $-29.2m (-17.7%) | $-26.6m (-12.7%) | — | $-0.03 |
| 2023 | $4.8m | $-49.7m (-70.4%) | $-22.9m (13.7%) | -1035.3% | $-0.06 (-100.0%) |
| 2024 | $28.9m (502.9%) | $-20.4m (58.9%) | $-43.9m (-91.8%) | -70.5% (93.2%) | $-0.01 (83.3%) |
| 2025 | $1.2m (-95.9%) | $-10.3m (49.6%) | $-8.1m (81.6%) | -871.8% (-1136.2%) | $0.00 (100.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.